Literature DB >> 22706868

Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression.

Joel F Gradowski1, Rachel L Sargent, Fiona E Craig, Kathleen Cieply, Kim Fuhrer, Carol Sherer, Steven H Swerdlow.   

Abstract

Cyclin D1 expression, usually absent in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), has been described in the proliferation centers (PC) of some CLL/SLL. The prevalence of this finding is uncertain, as is the explanation for its occurrence and whether these cases have any other unique features. Cyclin D1 immunohistochemical staining was therefore investigated in 57 extramedullary CLL/SLL biopsies. In 6 cases, cyclin D1 immunofluorescence followed by CCND1 fluorescence in situ hybridization (FISH) and PC targeted analysis was performed using a Bioview Duet system. Excluding the prospectively selected cases that had the targeted FISH studies, cyclin D1+ PC were identified in 20% of cases. The cyclin D1+ CLL did not appear pathologically or phenotypically distinctive, though 46% had an interfollicular growth pattern. The cyclin D1+ PCs were SOX11- and lacked CCND1 translocations and gains in 5 of 5 informative cases. The recognition of cyclin D1 expression in PC of a significant minority of CLL/SLL can be a diagnostic aid and should not lead to the diagnosis of focal mantle cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706868      PMCID: PMC3700540          DOI: 10.1309/AJCPIVKZRMPF93ET

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  48 in total

1.  The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.

Authors:  J D Hoyer; C A Hanson; R Fonseca; P R Greipp; G W Dewald; P J Kurtin
Journal:  Am J Clin Pathol       Date:  2000-06       Impact factor: 2.493

2.  Expression of cyclins D-type in B-chronic lymphoproliferative disorders.

Authors:  B Sola; G Roué; F Duquesne; H Avet-Loiseau; M Macro; V Salaün; X Troussard
Journal:  Leukemia       Date:  2000-07       Impact factor: 11.528

3.  Histological and immunoglobulin VH gene analysis of interfollicular small lymphocytic lymphoma provides evidence for two types.

Authors:  D W Bahler; N S Aguilera; C C Chen; S L Abbondanzo; S H Swerdlow
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells.

Authors:  B Falini; M Fizzotti; A Pucciarini; B Bigerna; T Marafioti; M Gambacorta; R Pacini; C Alunni; L Natali-Tanci; B Ugolini; C Sebastiani; G Cattoretti; S Pileri; R Dalla-Favera; H Stein
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

5.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

Authors:  L Granziero; P Ghia; P Circosta; D Gottardi; G Strola; M Geuna; L Montagna; P Piccoli; M Chilosi; F Caligaris-Cappio
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

6.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.

Authors:  Jenny Orchard; Richard Garand; Zadie Davis; Gavin Babbage; Surinder Sahota; Estella Matutes; Daniel Catovsky; Peter W Thomas; Hervé Avet-Loiseau; David Oscier
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

7.  Unsupervised immunophenotypic profiling of chronic lymphocytic leukemia.

Authors:  Luzette K Habib; William G Finn
Journal:  Cytometry B Clin Cytom       Date:  2006-05       Impact factor: 3.058

8.  Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas.

Authors:  H Stein; A Bonk; G Tolksdorf; K Lennert; H Rodt; J Gerdes
Journal:  J Histochem Cytochem       Date:  1980-08       Impact factor: 2.479

9.  Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes.

Authors:  Laurentia Nodit; David W Bahler; Samuel A Jacobs; Joseph Locker; Steven H Swerdlow
Journal:  Hum Pathol       Date:  2003-10       Impact factor: 3.466

10.  Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody.

Authors:  Wah Cheuk; Kathy O Y Wong; Cesar S C Wong; John K C Chan
Journal:  Am J Surg Pathol       Date:  2004-06       Impact factor: 6.394

View more
  5 in total

Review 1.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

Review 2.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 3.  Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.

Authors:  Leticia Quintanilla-Martinez; Birgitta Sander; John K C Chan; Luc Xerri; German Ott; Elias Campo; Steven H Swerdlow
Journal:  Virchows Arch       Date:  2015-09-28       Impact factor: 4.064

Review 4.  Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Authors:  Ryan C Lynch; Dita Gratzinger; Ranjana H Advani
Journal:  Curr Treat Options Oncol       Date:  2017-07

5.  The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center.

Authors:  Hui Wang; Xiaojuan Yu; Xu Zhang; Suxia Wang; Minghui Zhao
Journal:  Diagn Pathol       Date:  2021-07-04       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.